Disclosure Panels Details Page

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel - Disclosures as of 05/22/2020

Panel Member
(Spouse/Domestic Partner/Dependent)
Clinical Research Support/Data Safety Monitoring Board Scientific Advisory Boards, Consultant, or Expert Witness Promotional Advisory Boards, Consultant, or Speakers Bureau Employment/ Governing Board, Patent, Equity, or Royalty Has Attended
Michael Berry MD, FACS None None None None -
Marian Birkeland PhD None None None None -
Saundra Buys MD None None None None -
Mary Daly MD, PhD, FACP None None None None
Susan Darlow PhD None None None None
Patricia Dickson MD None None None None
Susan Domchek MD None AstraZeneca Pharmaceuticals LP None None
Mary Dwyer MS None None None None
Ahmed Elkhanany MD None None None None
Susan Friedman DVM None None AstraZeneca Pharmaceuticals LP
Bristol Myers Squibb
InformedDNA
Pfizer Inc.
None -
Judy Garber MD, MPH None Ambry Genetics
Gtx Pharmaceuticals - SPOUSE
Helix
Invitae Genetics
Konica Minolta
Novartis Pharmaceuticals Corporation
Oric Pharmaceuticals - SPOUSE
None None -
Michael Goggins MD None None None None
Kristina Gregory MSN, RN None None None None -
Laura Hanisch PsyD None None None None -
Mollie Hutton MS, CGC None None None None -
Seema Khan MD None None None None
Catherine Klein MD None None None None -
Wendy Kohlmann MS, CGC None None None None
Allison Kurian MD, MSc Myriad Genetic Laboratories, Inc. None None None -
Christine Laronga MD, FACS None None None None
Jennifer Litton MD AstraZeneca Pharmaceuticals LP
EMD Serono
Genentech, Inc.
GSK
Paxman Coolers Limited
Pfizer Inc.
Zenith Pharmaceuticals
AstraZeneca Pharmaceuticals LP
Ayala
Pfizer/Medivation
Clinical Care Options
Med Learning Group
medscape
Physician education Resource
Prime Oncology
UpToDate
Up To Date
Julie Mak MS, MSc, CGC None None None None
Carolyn Menendez MD None None None None
Sofia Merajver MD, PhD Founder and equity interest in InheRET, Inc None None Founder and equity interest in InheRET, Inc. I do not believe that any change in the guidelines would benefit or harm the commercial potential of InheRET, Inc. -
Barbara Norquist MD None None None None -
Kenneth Offit MD, MPH None None None None
Tuya Pal MD None None None None
Holly Pederson MD None None None None -
Robert Pilarski MS, MSW, LGC None None None None
Gwen Reiser MS, CGC None None None None
Kristen Shannon MS, CGC None None None None -
Rebecca Shatsky MD Biocept
Genentech, Inc.
Oncternal Inc.
None None None -
Kala Visvanathan MD, MHS Cepheid None None None
Jeffrey Weitzel MD None None AstraZeneca Pharmaceuticals LP None
Myra Wick MD, PhD None InformedDNA None None -
Kari Wisinski MD AstraZeneca Pharmaceuticals LP
Novartis Pharmaceuticals Corporation
Pfizer Inc.
sanofi-aventis U.S.
None None None
Matthew Yurgelun MD None Janssen Pharmaceutica Products, LP None None -